Streamlining manufacturing licence timelines for medical devices is necessary but not sufficient to make India a global medical devices hub. Examine.

India's medical devices sector, valued at about USD 11 billion, aspires to reach USD 50 billion by 2030 [2]. The Health Ministry's June 2026 draft amendment to the Medical Devices Rules, 2017 — cutting the Class C/D manufacturing licence timeline from 105 to 90 days [1] — is a welcome but partial step towards hub status.

Why streamlining is necessary

• Cuts time-to-market: defined timelines for each stage — application scrutiny, notified-body audit, compliance verification and licence issue — reduce discretion and delay [1].
• Risk-proportionate regulation: lighter touch for low-risk Class A/B devices under State Licensing Authorities, stricter central scrutiny by CDSCO for high-risk stents and implants [3].
• Investor confidence: predictable clearances lower compliance costs, a core demand of the National Medical Devices Policy 2023, whose first strategic pillar is regulatory streamlining [2].
• Preserves safety: quality, safety and performance requirements remain intact, so speed is not traded against patient protection [1].

Why it is not sufficient

• Import dependence in high-value segments: MRI, CT, linear accelerators and mammography units remain largely imported; PLI-backed greenfield units have only recently begun production [4].
• Weak component ecosystem: sensors, medical-grade polymers and electronics are still sourced abroad, so licensing speed does not fix input costs.
• R&D and innovation deficit: India competes on low-margin consumables, not Class C/D innovation, which needs sustained research funding and clinical-trial infrastructure.
• Regulatory capacity: faster statutory timelines demand more trained assessors, accredited notified bodies and robust post-market surveillance, especially where Class A relies on self-certification [3].
• Global market access: exports need harmonisation with IMDRF norms and mutual recognition, beyond domestic licensing reform.

Licensing reform removes a procedural bottleneck; hub status requires the structural depth behind it. A convergent push — PLI-driven component manufacturing [4], medical device parks, strengthened CDSCO capacity and international regulatory harmonisation — can turn the six pillars of the 2023 Policy into reality [2], advancing both Atmanirbhar Bharat and affordable universal healthcare.